Biotech Week : Boston, 2026

When a biotech plans its first-in-human study, the anxiety almost always sits with the science. In practice, the science is rarely what breaks the timeline. Execution is.

Whether you’re an emerging company mapping your first trip to the clinic or a management team lining up the next round, the Phase 1 readout is the inflection point. It’s what turns a story into a de-risked asset, and it’s a large part of what the room is really pricing. Yet the operational choices that decide whether that readout lands on time, and whether the data travels, are often made late and treated as logistics rather than strategy.

Three execution risks tend to be underestimated:

Regulatory start-up. The weeks between “ready” and “dosing” are where timelines quietly disappear. A predictable ethics and governance pathway is worth far more than it looks on a Gantt chart.

Recruitment. Your protocol assumes cohorts fill on schedule. When they don’t, or when you need a make-up group, the delay hits your critical path and your budget at once, and it weakens your position in the next financing conversation.

Data acceptability. For a first-in-human asset, data that isn’t accepted cleanly by regulators is a problem you tend to discover far too late.

None of these are scientific problems. They’re a function of where you run the study and who runs it. This makes site selection a strategic decision, not a procurement one, and one worth making early.

At Scientia, we’ve completed 300+ first-in-human studies. For three years running we’ve filled every healthy volunteer and patient cohort on time, with no make-up groups. IRB approvals land in four to six weeks, our data is accepted by all the major global regulators from day one, and we’re operational 24/7.

The science is your edge. Making sure the execution protects it is ours.